Related Experiment Video
Updated: Jun 27, 2026
09:19
High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
Published on: January 4, 2015
Why are MSCs therapeutic? New data: new insight.
1Skeletal Research Center, Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA. arnold.caplan@case.edu
The Journal of Pathology
|November 22, 2008
Summary
Mesenchymal stem cells (MSCs) naturally act as pericytes, migrating to injury sites to release factors that promote healing and reduce immune response. This discovery enables new clinical trials using allogeneic MSCs.
Area of Science:
- Regenerative Medicine
- Cell Biology
- Immunology
Background:
- Mesenchymal stem cells (MSCs) possess multipotent differentiation capabilities.
- The natural function and in vivo niche of MSCs remain areas of active investigation.
- Recent insights suggest MSCs reside perivascularly, acting as pericytes.
Purpose of the Study:
- To elucidate the natural role of adult marrow-derived mesenchymal stem cells (MSCs).
- To identify the in vivo niche and primary functions of MSCs.
- To explore the therapeutic potential of MSCs based on their natural behavior.
Main Methods:
- Review of current scientific literature and clinical observations.
- Analysis of MSC behavior at sites of tissue injury.
- Characterization of bioactive factors secreted by MSCs.
Main Results:
- MSCs are identified as perivascular cells (pericytes) that migrate to injury sites.
- Released MSCs secrete potent immunomodulatory and trophic factors.
- Trophic factors inhibit apoptosis and scarring, while promoting angiogenesis and progenitor cell mitosis.
- Immunomodulatory effects suppress lymphocyte surveillance, preventing autoimmunity.
Conclusions:
- MSCs function naturally as pericytes, orchestrating tissue repair through secreted factors.
- The immunomodulatory properties of MSCs facilitate the use of allogeneic and xenogeneic cells in clinical settings.
- This understanding opens new avenues for MSC-based regenerative medicine and clinical trials.
